Table 1.
Trials' Characteristics.
| Authors | Pts | Dose RT (Gy) | Arms (mo.) | Median F.U. |
End-Points | Median PSA (ng/mL) |
N° of pts (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Primary | Secondary | Gleason Score 7-10 |
T3-T4 | ||||||
| Laverdiere et al | 148 148 |
64 | 5 (AS) 10 (AS) |
3.7 yrs | BDFS, CDFS | - | 11.9 12.7 |
82 (27.6) | 40 (13.4) |
| Crook et al | 177 184 |
66 | 3 (GF) 8 (GF) |
79 mo. | OS, CSS, DFS | - | 8.9 10.1 |
178 (49.3) | 48 (13.2) |
| Horwitz et al | 763 758 |
65-70 | 4 (GF) 24 (GF) |
10 yrs | DFS | OS, BF, DMF | 20.8 19.8 |
838 (55.1) | 829 (54.5) |
| Bolla et al | 483 487 |
70 | 6 (CAB) 36 (CAB) |
5.2 yrs | OS, CPFS, DS, BPFS | - | 18.8 18.8 |
479 (49.3) | 754 (77.7) |
| Armstrong et al | 127 134 |
50-74 | 4 (CAB) 8 (CAB) |
102 mo. | BF | OS, CSS | 17.0 13.6 |
153 (55.4) | 159 (57.6) |
Pts: patients; RT: radiotherapy; Gy: gray; mo.: months; F.U.: follow-up; PSA: serum prostate-specific antigen; N°: number; AS: androgen suppression; yrs: years; BDFS: biochemical disease free survival; CDFS: clinical disease free survival; GF: goserelin + flutamide; OS: overall survival; CSS: cancer specific survival; DFS: disease free survival; BF: biochemical failure; DMF: distant metastases failure; CAB: complete androgen blockade; CPFS: clinical progression free survival; BPFS: biochemical progression free survival: BF: biochemical failure.